What influences adherence to guidance for post-operative instillation of intravesical chemotherapy to bladder cancer patients?

Overactive BladderUro-Oncology

Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients

Eur Urol.

Bosschieter J, Nieuwenhuijzen JA, van Ginkel T, Vis AN, Witte B, Newling D, Beckers GMA, van Moorselaar RJ

doi: 10.1016/j.eururo.2017.06.038.

Overactive BladderUro-Oncology

An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups

Urol Oncol.

Bosschieter J, Nieuwenhuijzen JA, Vis AN, van Ginkel T, Lissenberg-Witte BI, Beckers GMA, van Moorselaar RJA

doi: 10.1016/j.urolonc.2018.05.026.

Overactive BladderUro-Oncology

Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer

Eur Urol Focus.

Tabayoyong WB, Kamat AM, O'Donnell MA, McKiernan JM, Ray-Zack MD, Palou J, Brausi M, Black PC, Williams SB

doi: 10.1016/j.euf.2018.08.019.

Uro-Oncology

Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer

Nat Rev Urol.

Joice GA, Bivalacqua TJ, Kates M

doi: 10.1038/s41585-019-0220-4.

Uro-Oncology

Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin

Eur Urol.

Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, Poch MA, Sexton WJ, Black PC, McKiernan JM, Steinberg GD, Kamat AM, Gilbert SM

doi: 10.1016/j.eururo.2020.02.012.

Uro-Oncology

No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy: a nation-wide register-based study

World J Urol.

Jerlström T, Chen R, Liedberg F, Andrén O, Ströck V, Aljabery FAS, Hosseini A, Sherif A, Malmström PU, Ullén A, Gårdmark T, Fall K

doi: 10.1007/s00345-019-02770-2

Uro-Oncology

The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy

World J Urol.

Renninger M, Fahmy O, Schubert T, Schmid MA, Hassan F, Stenzl A, Gakis G

doi: 10.1007/s00345-019-02780-0.

Overactive BladderUro-OncologyPregnancy and Childbirth

Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population

Clin Genitourin Cancer.

Robinson AG, Wei X, Vera-Badillo FE, Mackillop WJ, Booth CM

doi: 10.1016/j.clgc.2016.12.025.

Overactive BladderUro-Oncology

High neutrophil-to-lymphocyte ratio predicts worse overall survival in patients with advanced/metastatic urothelial bladder cancer

Int J Urol.

Tan YG, Eu EWC, Huang HH, Lau WKO

doi: 10.1111/iju.13480.

Related content

Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients

An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups

Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer

Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer

Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin

No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy: a nation-wide register-based study

The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy

Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population

High neutrophil-to-lymphocyte ratio predicts worse overall survival in patients with advanced/metastatic urothelial bladder cancer